Poor oral health is associated with a 75% increased risk of hepatocellular carcinoma (HCC), the most common form of liver cancer, new research published in UEG Journal has found.
Researchers have shown that genes regulating iron metabolism in the body are responsible for excess liver iron. High levels of iron in the liver are linked to a number of serious health conditions including cancer, diabetes, high blood pressure and cardiovascular as well as liver disease. But measuring liver iron is difficult and until recently could only be done through an invasive biopsy.
In experiments with mice, Brazilian scientists demonstrated that a moderate training protocol reduced liver fat and made the organ more sensitive to insulin, even before loss of body weight occurred.
A new blood test could become clinical practice within five years, reducing the need for a liver biopsy in the management of pediatric non-alcoholic fatty liver disease (NAFLD), as a major new international pediatric liver registry collaboration yields early results.
For patients taking proton pump inhibitors (PPIs) to treat gastroesophageal disease (GERD) or other acid-related conditions, new research puts safety concerns to rest. In a large, multi-year, randomized trial studying the safety of proton pump inhibitors (PPIs), researchers find no evidence to support claims that PPIs cause serious health issues such as pneumonia, chronic kidney disease, diabetes and dementia. This research is published in Gastroenterology, the official journal of the American Gastroenterological Association, as an article in press.
Scientists from Trinity College Dublin have discovered how the highly infectious and sometimes deadly hepatitis C virus (HCV) 'ghosts' our immune system and remains undiagnosed in many people. By targeting a specific protein, scientists hope to restore effective immune responses against HCV, particularly in patients who do not respond to existing therapy.
One of the most exciting advancements in stem cell research has been the development of organoid systems, which are organ-like three-dimensional structures that mimic their corresponding organ in vivo. In this important review in Digestive and Liver Disease, published by Elsevier, scientists highlight some of the established and exciting novel uses for organoids or 'organs in a dish' in gastroenterology and hepatology and look towards the future in this exciting field.
Scientists successfully bioengineered human liver organoids that faithfully mimic key features of fatal liver disease in the laboratory. This allowed them to uncover underlying disease biology in the organoids and test a potential therapy that in preclinical lab tests reversed an often-fatal childhood condition called Wolman disease. In findings published online by the journal Cell Metabolism, study overcomes major hurdles to unraveling the molecular mysteries of liver diseases and finding desperately needed new therapies.
Researchers from the Hubrecht Institute developed a human model in which they use organoids, or mini organs, to study the function of specific genes that are mutated in liver cancer. Using this method, they have found that mutations in BAP1, a gene commonly mutated in liver cancer, changes the behavior of the cells, which may make them more likely to be invasive. Their results were published in Cell Stem Cell.
A new treatment approach that involves blocking a protein has, for the first time, shown promising results in the treatment of fatty liver disease, in a landmark translational research collaboration between Duke-NUS Medical School, National Heart Centre Singapore and biotech company Enleofen Bio.